Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

Shukui Qin,Jin Li,Haijun Zhong,Chuan Jin,Lili Chen,Xianglin Yuan,Qingxia Fan,Kehe Chen,Peiguo Cao,Jianjun Xiao,Da Jiang,Tao Zhang,Hongyu Zhang,Xicheng Wang,Wei Wang,Qingyu Wang

Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

2021

Shukui Qin
Jin Li
Haijun Zhong
Chuan Jin
Lili Chen
Xianglin Yuan
Qingxia Fan
Kehe Chen
Peiguo Cao
Jianjun Xiao
Da Jiang
Tao Zhang
Hongyu Zhang
Xicheng Wang
Wei Wang
Qingyu Wang

2566Background: Microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) in cells render them susceptible to immune checkpoint blockages. This study aimed to evaluate the efficacy and...

Keywords:

previously treated
in patient
anti pd 1
Cancer research
Microsatellite instability
DNA mismatch repair
Phases of clinical research
Medicine
Immune checkpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations